Compare Novartis AG (NVS) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs SOLAI Limited — how do they compare? Novartis AG trades at $152.38 (market cap $295.37B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Novartis AG is far larger — about 17697.4× SOLAI Limited's market cap, and Novartis AG pays a 3.07% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| NVS | SLAI | |
|---|---|---|
Market Cap | $295.37B | $16.69M |
Sector | Health | Technology |
52-Week High | $168.62 | $26.74 |
52-Week Low | $119.31 | $2.74 |
Enterprise Value | $336.69B | $16.33M |
Dividend Yield | 3.07% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
